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Patients with malignant ascites (MAs) display several symptoms, such as dyspnea,
nausea, pain, and abdominal tenderness, resulting in a significant reduction in
their quality of life. Tumor-associated macrophages (TAMs) play a crucial role in
MA progression. Because TAMs have a tumor-promoting M2 phenotype, conver-
sion of the M2 phenotypic function of TAMs would be promising for MA treat-
ment. Nuclear factor-jB (NF-jB) is a master regulator of macrophage polarization.
Here, we developed targeted transfer of a NF-jB decoy into TAMs by ultrasound
(US)-responsive, mannose-modified liposome ⁄NF-jB decoy complexes (Man-PEG
bubble lipoplexes) in a mouse peritoneal dissemination model of Ehrlich ascites
carcinoma. In addition, we investigated the effects of NF-jB decoy transfection
into TAMs on MA progression and mouse survival rates. Intraperitoneal injection
of Man-PEG bubble lipoplexes and US exposure transferred the NF-jB decoy into
TAMs effectively. When the NF-jB decoy was delivered into TAMs by this method
in the mouse peritoneal dissemination model, mRNA expression of the Th2 cyto-
kine interleukin (IL)-10 in TAMs was decreased significantly. In contrast, mRNA
levels of Th1 cytokines (IL-12, tumor necrosis factor-a, and IL-6) were increased
significantly. Moreover, the expression level of vascular endothelial growth fac-
tor in ascites was suppressed significantly, and peritoneal angiogenesis showed a
reduction. Furthermore, NF-jB decoy transfer into TAMs significantly decreased
the ascitic volume and number of Ehrlich ascites carcinoma cells in ascites, and
prolonged mouse survival. In conclusion, we transferred a NF-jB decoy efficiently
by Man-PEG bubble lipoplexes with US exposure into TAMs, which may be a
novel approach for MA treatment.
A variety of abdominal tumors, such as ovarian, pancre-atic, gastric, and colorectal malignancies, are often
accompanied by MAs.(1–4) Patients with MAs display several
symptoms, including abdominal pain, respiratory distress, nau-
sea, and anorexia, resulting in a significant reduction of their
quality of life.(1–4) In addition, MAs are associated with poor
prognoses.(5,6)
Malignant ascites are known to contain an abundance of leu-
kocytes.(7,8) In particular, macrophages are major components of
the MA microenvironment, and these TAMs are critically
involved in MA progression.(9–11) It has been reported that either
depletion or functional regulation of TAMs suppresses the accu-
mulation of ascites and proliferation of cancer cells.(12–14)
Macrophages are generally classified into two phenotypes,
M1 and M2, according to their characteristics of humoral fac-
tor production and gene expression.(15,16) M1 (classically acti-
vated) macrophages have an antitumor potency based on the
expression of Th1 cytokines (e.g. IL-12, TNF-a, and IL-6) and
nitric oxide production. In contrast, M2 (alternatively acti-
vated) macrophages show tumor-promoting effects through
expression of several cytokines and pro-tumor factors, such as
IL-10, VEGF, and MMPs. Because a large proportion of
TAMs are known to show the M2 phenotype,(17–19) phenotypic
conversion of TAMs from M2 to M1 would be a promising
approach for MA treatment.(20–22)
Recently, it has been reported that inhibition of NF-jB
expression and activation can suppress the phenotypic conver-
sion of TAMs to M2.(23–25) We have previously reported that
NF-jB inhibition using oligonucleotides, such as siRNA and
NF-jB decoy oligonucleotides, show the potential to convert
the phenotype of TAMs from M2 toward M1.(26,27) Recently,
we have developed US-responsive, mannose-modified liposome
⁄NF-jB decoy complexes (or Man-PEG bubble lipoplexes) for
targeting mannose receptors that are highly expressed on the
surface of TAMs, and achieved TAM-targeted NF-jB transfec-
tion into solid tumors by US exposure in tumor-bearing
mice.(27) Based on these findings, we hypothesized that Man-
PEG bubble lipoplexes with US exposure in the abdominal area
may introduce a NF-jB decoy efficiently into TAMs existing in
MAs, resulting in a therapeutic effect.
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In the present study, we determined the efficiency of NF-jB
decoy transfection by i.p. injection of Man-PEG bubble lipo-
plexes combined with transdermal US exposure in the abdomi-
nal area of EAC-bearing mice. Furthermore, we investigated
the effects of NF-jB decoy transfection by this method on the
tumor-promoting phenotype of TAMs as well as MA progres-
sion.
Materials and Methods
Animals and cell lines. Female ddY mice (4–5 weeks old)
were purchased from the Shizuoka Agricultural Cooperative
Association for Laboratory Animals (Shizuoka, Japan). All ani-
mal experiments were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals as adopted
and promulgated by the US National Institutes of Health
(Bethesda, MD, USA) and the Guidelines for Animal Experi-
ments of Kyoto University (Kyoto, Japan). The protocol was
approved by the Kyoto University Animal Experimentation
Committee (approval no. 2013-44). All surgery was carried out
under sodium pentobarbital anesthesia, and all efforts were
made to minimize suffering. The EAC cells were obtained
from the Riken Bioresource Center (Osaka, Japan). Cells were
cultured in DMEM supplemented with 10% heat-inactivated
FBS, penicillin G (100 U ⁄mL), and streptomycin (100 lg ⁄mL)
at 37°C in 5% CO2.
Nuclear factor-jB decoy oligonucleotides. Nuclear factor-jB
decoy oligonucleotides, FAM-labeled NF-jB decoy oligonu-
cleotides, and random decoy oligonucleotides were phosphoro-
thioated and kindly provided by AnGes MG (Osaka, Japan).
The sequences of the decoy were as follows. Nuclear factor-
jB decoy: sense, GGAGGGAAATCCCTTCAAGG and anti-
sense, CCTCCCTTTAGGGAAGTTCC; random decoy: sense,
TTGCCGTACCTGACTTAGCC and antisense, AACGGCATG
GACTGAATCGG.
Construction of Man-PEG bubble lipoplexes. Man-PEG bubble
lipoplexes were constructed according to our previous
reports.(27,28) Briefly, to produce the liposomes for bubble lipo-
plexes, DSDAP, DSPC, and NH2-PEG-DSPE (Avanti Polar
Lipids Inc., Alabaster, AL, USA) or mannose-modified
PEGDSPE (Man-PEG-DSPE) were mixed in chloroform at a
molar ratio of 7:2:1. The liposome construction mixture was
dried by evaporation, vacuum desiccated, and the resultant
lipid film was resuspended in a sterile 5% glucose solution.
After hydration for 30 min at 65°C, the dispersion was soni-
cated for 10 min in a bath-type sonicator and then in a tip-type
sonicator for 3 min to produce liposomes. The liposomes were
sterilized by passing through a 0.45-lm membrane filter
(Nihon-Millipore, Tokyo, Japan). Lipoplexes were prepared by
gently mixing with equal volumes of NF-jB decoy and lipo-
some solution at a charge ratio of 1.0:2.3 (:+). To enclose
US imaging gas in lipoplexes, perfluoropropane gas (Tak-
achiho Chemical Industries, Tokyo, Japan) was applied to pre-
pare lipoplexes under pressure, which were sonicated using a
bath-type sonicator (AS ONE, Osaka, Japan) for 5 min. The
particle sizes and ξ-potentials of liposomes ⁄ lipoplexes were
determined by a Zetasizer Nano ZS instrument (Malvern
Instruments, Malvern, UK).
Separation of F4 ⁄ 80+ cells (TAMs) from tumor ascites. Ehrlich
ascites carcinoma cells (1 9 106 cells) were inoculated i.p.
into mice. The ascites were then harvested at predetermined
times post-inoculation. F4 ⁄80+ cells were separated by mag-
netic cell sorting with a phycoerythrin-labeled anti-mouse
F4 sol;80 antibody (Bay Bioscience, Hyogo, Japan), phycoery-
thrin-positive selection kit, and EasySep (Veritas, Tokyo,
Japan) following the manufacturer’s instructions.
In vivo internalization study. At 4 days post-i.p. inoculation
of EAC cells into mice, 200 lL of bubble lipoplexes con-
structed with the FAM-labeled NF-jB decoy (10 lg NF-jB
decoy) was injected i.p. At 5 min post-injection, US (fre-
quency, 1.056 MHz; duty, 50%; burst rate, 10 Hz; intensity,
1.0 W ⁄ cm2; time, 2 min) was exposed transdermally to the
abdominal area using a Sonopore-4000 sonicator (NEPA
GENE, Chiba, Japan) with a probe of 20 mm in diameter. At
1 h post-injection, the ascites were harvested to separate the
TAMs. The cell-associated fluorescence in 10 000 cells was
measured using a BD FACSCanto II Flow Cytometer (Becton
Dickinson, Tokyo, Japan).
In vivo NF-jB decoy transfection. The EAC-bearing mice
were i.p. injected with 200 lL Bare-PEG or Man-PEG bubble
lipoplexes (10 lg NF-jB decoy). At 5 min post-injection, US
(frequency, 1.056 MHz; duty, 50%; burst rate, 10 Hz; inten-
sity, 1.0 W ⁄ cm2; time, 2 min) was exposed transdermally to
the abdominal area using the Sonopore-4000 sonicator and
20-mm-diameter probe.
Measurement of intranuclear NF-jB. At 4 days after inocula-
tion of EAC cells into mice, we carried out in vivo NF-jB
decoy transfection. After 12 h of in vivo NF-jB decoy trans-
fection, the ascites were harvested, and TAMs were separated
from ascites. Nuclear extracts of the TAMs were prepared
using a Nuclear Extract Kit (Active Motif, Carlsbad, CA,
USA). Nuclear proteins were stored at 80°C until use. The
protein concentration was measured with a Protein Quantifica-
tion Kit (Dojindo Molecular Technologies, Tokyo, Japan). The
amounts of p50 and p65, which are the components of NF-jB,
in the nuclear extracts were measured using a TransAM NFjB
Family Kit (Active Motif) according to the recommended pro-
cedures.
Quantitative RT-PCR. At 4 days after inoculation of EAC
cells into mice, we carried out in vivo NF-jB decoy transfec-
tion. After 24 h of in vivo NF-jB decoy transfection, the asci-
tes were harvested, and TAMs were separated from ascites.
Total RNA was isolated from TAMs using a GenElute Mam-
malian Total RNA Miniprep Kit (Sigma-Aldrich, St. Louis,
MO, USA). Reverse transcription of mRNA was carried out
using a PrimeScript RT reagent Kit (Takara Bio, Shiga, Japan).
Detection of cDNAs (IL-10, IL-12p70, TNF-a, IL-6, VEGF-A,
and GAPDH) was carried out by real-time PCR using SYBR
Premix Ex Taq (Takara Bio) and a LightCycler Quick System
350S (Roche Diagnostics, Indianapolis, IN, USA). The primers
for IL-10, IL-12, TNF-a, IL-6, and GAPDH cDNAs were as
follows: IL-10, 50-GCT CTT ACT GAC TGG CAT GAG-30
(forward) and 50-CGC AGC TCT AGG AGC ATG TG-30
(reverse); IL-12, 50-ACT CTG CGC CAG AAA CCT C-30
(forward) and 50-CAC CCT GTT GAT GGT CAC GAC-30
(reverse); TNF-a, 50-CCT CCC TCT CAT CAG TTC TA-30
(forward) and 50-ACT TGG TGG TTT GCT ACG AC-30
(reverse); IL-6, 50-TAG TCC TTC CTA CCC CAA TTT CC
-30 (forward) and 50-TTG GTC CTT AGC CAC TCC TTC-30
(reverse); VEGF-A, 50- AGC ACA GCA GAT GTG AAT GC-
30 (forward) and 50-AAT GCT TTC TCC GCT CTG AA-30
(reverse); and GAPDH, 50-TCT CCT GCG ACT TCA ACA-30
(forward) and 50-GCT GTA GCC GTA TTC ATT GT-30
(reverse).
Measurement of VEGF concentrations in ascites. At 2 days
after inoculation of EAC cells into mice, in vivo NF-jB decoy
transfection was carried out three times every other day (days
2, 4, and 6 after inoculation of EAC cells). Ascites were har-
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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vested at 10 days after EAC cell inoculation. The ascites were
centrifuged at 10 000 g for 10 min at 4°C and the resultant
supernatant was applied to a commercial ELISA kit (Pepro-
Tech, Rocky Hill, NJ, USA) to measure the concentration of
VEGF.
Determination of angiogenesis. At 2 days after inoculation of
EAC cells, in vivo NF-jB decoy transfection was carried out
three times every other day (days 2, 4, and 6 after inoculation
of EAC cells). At 10 days after EAC cell inoculation, the mice
were photographed, their peritoneum was cut open, and then
the inner lining of the peritoneal cavity was photographed.
Measurement of ascitic fluid. At 2 days after inoculation of
EAC cells, in vivo NF-jB decoy transfection was carried out
three times every other day (days 2, 4, and 6 after inoculation
of EAC cells). At 10 days after EAC cell inoculation, the vol-
ume of the ascitic fluid was determined by aspiration with a
needle and syringe.
Measurement of the number of EAC cells in ascites. To mea-
sure EAC cell numbers, EAC cells with stable expression of
the firefly luciferase gene (EAC ⁄Luc) were established as
reported previously.(29) At 2 days after inoculation of EAC
⁄Luc cells into mice, in vivo NF-jB decoy transfection was car-
ried out three times every other day (days 2, 4, and 6 after inoc-
ulation of EAC cells). After 10 days of EAC ⁄Luc cell
inoculation, 500 lL ascites was harvested and mixed with an
equal volume of lysis buffer (0.05% Triton X-100, 2 mM
EDTA, and 0.1 M Tris, pH 7.8). Then the mixed solution was
centrifuged at 10 000 g for 10 min at 4°C. The supernatant
was mixed with luciferase assay buffer (Picagene; Toyo Ink,
Tokyo, Japan) and the luciferase activity was measured in a lu-
minometer (Lumat LB 9507; EG&G Berthold, Bad Wildbad,
Germany). The luciferase activity in the ascites was converted
to the number of EAC ⁄Luc cells using a regression line.
Measurement of the body weight and survival rates of EAC-
bearing mice. The body weight of EAC-bearing mice was mea-
sured every day until the death of the first mice. The survival of
mice was monitored up to 60 days after EAC cell inoculation.
Statistical analysis. Results are presented as the mean  SD
of more than three experiments; ANOVA was used to test the
statistical significance of differences among groups. Two-group
comparisons were carried out using Student’s t-test. Multiple
comparisons between control groups and other groups were
carried out by Dunnett’s test, and multiple comparisons
between all groups used the Tukey–Kramer test. Survival
curves were compared using the log–rank test.
Results
Physicochemical properties of bubble lipoplexes. The physico-
chemical properties of bubble lipoplexes were evaluated by
measuring the particle sizes and f-potentials. Mean particle
sizes and f-potentials of Bare-PEG and Man-PEG bubble lipo-
plexes were approximately 550 nm and +20 mV, respectively
(Table 1). These results are comparable with our previous
report.(27)
In vivo NF-jB decoy transfer into TAMs. We carried out
in vivo TAM-targeted NF-jB decoy transfer by Man-PEG bub-
ble lipoplexes constructed with a FAM-labeled NF-jB decoy
combined with US exposure. The amount of FAM-labeled NF-
jB decoy introduced into TAMs by Man-PEG bubble lipoplex-
es and US exposure was eightfold higher than that by
Man-PEG bubble lipoplexes without US exposure (Fig. 1).
Moreover, this level of FAM-labeled NF-jB decoy transfection
by Man-PEG bubble lipoplexes and US exposure was much
higher than that by Bare-PEG bubble lipoplexes and US expo-
sure. Similarly, intranuclear p50 and p65 levels in TAMs were
significantly decreased by NF-jB decoy transfer using Man-
PEG bubble lipoplexes and US exposure (Fig. 2).
Change of cytokine mRNA expression in TAMs. Because the
phenotype of macrophages is generally classified according to
the profile of cytokine expression,(15,16) we assessed the
expression levels of cytokine mRNA in TAMs transfected with
the NF-jB decoy. Expression of IL-10 mRNA in TAMs trans-
fected with the NF-jB decoy by Man-PEG bubble lipoplexes
and US exposure was the lowest among all groups (Fig. 3a).
In contrast, mRNA expression levels of IL-12, TNF-a, and IL-
6 in TAMs transfected with the NF-jB decoy by Man-PEG
bubble lipoplexes and US exposure were significantly higher
compared with those in other groups (Fig. 3b–d).
Suppressive effect of NF-jB decoy transfection on tumor angio-
genesis. Angiogenesis is a critical event for the progression of
MA.(30–32) Because VEGF predominantly regulates angiogene-
sis,(33,34) the level of VEGF in tumor ascites and the expres-
sion levels of VEGF mRNA in TAMs were determined after
NF-jB decoy transfection into TAMs. As shown in Fig-
ure 4(a), the concentration of VEGF in the ascites was signifi-
cantly low in mice transfected with the NF-jB decoy by
Man-PEG bubble lipoplexes and US exposure. In addition,
expression of VEGF mRNA in TAMs transfected with the NF-
jB decoy by Man-PEG bubble lipoplexes and US exposure
was the lowest among all groups (Fig. 4b). Moreover, we eval-
uated the degree of angiogenesis in the peritoneum after NF-
jB decoy transfection into TAMs. As shown in Figure 4(c),
suppressed angiogenesis in the peritoneum was observed in
mice transfected with the NF-jB decoy by Man-PEG bubble
lipoplexes and US exposure.
Antitumor effects of NF-jB decoy transfection into TAMs on
EAC-bearing mice. Finally, we examined the antitumor effects
of NF-jB decoy transfection into TAMs using Man-PEG bub-
ble lipoplexes and US exposure against MA. The strongest
inhibitory effect on EAC cell proliferation in ascites and ascit-
ic fluid increase was observed by NF-jB decoy transfection
into TAMs using Man-PEG bubble lipoplexes and US expo-
sure (Fig. 5a,b). In addition, the increase of body weight was
significantly suppressed and the survival of EAC-bearing mice
was significantly prolonged by NF-jB decoy transfection into





Bare-PEG bubble liposome (DSDAP:DSPC:
NH2-PEG2000-DSPE = 7:2:1 [mol])
561.1  6.3 34.4  1.4
Man-PEG bubble liposome (DSDAP:DSPC:
Man-PEG2000-DSPE = 7:2:1 [mol])
556.2  3.9 35.8  0.7
Bare-PEG bubble lipoplex (DSDAP:DSPC:
NH2-PEG2000-DSPE = 7:2:1 [mol])
550.8  5.7 19.9  2.2
Man-PEG bubble lipoplex (DSDAP:DSPC:
Man-PEG2000-DSPE = 7:2:1 [mol])
557.6  4.9 19.6  3.1
Bare-PEG bubble liposome, ultrasound (US)-responsive and mannose-
unmodified liposome; DSDAP, 1,2-distearoyl-sn-glycero-3-dimethylam-
monium propane, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPC,
1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE, 1,2-distearoyl-sn-gly-
cero-3-phosphoethanolamine; Man-PEG bubble liposome, US-respon-
sive and mannose-modified liposome; Bare-PEG bubble lipoplex, US-
responsive and mannose-unmodified liposome ⁄ nuclear factor (NF)-jB
decoy complexes; Man-PEG bubble lipoplex, US-responsive and man-
nose-modified liposome ⁄NF-jB decoy complexes.
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TAMs using Man-PEG bubble lipoplexes and US exposure
(Fig. 5c,d).
Discussion
In this study, we applied the combined use of Man-PEG bub-
ble lipoplexes and US exposure for TAM-targeted delivery of
a NF-jB decoy in EAC-bearing mice. Man-PEG bubble lipo-
plexes possess the following two hallmarks: (i) mannose
receptor-mediated cell-selective targeting; and (ii) direct deliv-
ery of nucleic acids into the cytoplasm by “sonopora-
tion.”(28,35–37) Because TAMs are known to express high
levels of mannose receptor on their surface,(9,38) we hypothe-
sized that Man-PEG bubble lipoplexes would achieve efficient
delivery of a NF-jB decoy into TAMs in EAC-bearing mice.
We showed that the combined use of Man-PEG bubble lipo-
plexes with US exposure was able to introduce the NF-jB
decoy into TAMs compared with using Bare-PEG bubble
lipoplexes and US exposure or Man-PEG bubble lipoplexes
without US exposure (Fig. 1). As we previously showed that
a large proportion of Man-PEG bubble lipoplexes was bound
to the surface of macrophages, not internalized by endocyto-
sis, at 5 min after the addition of Man-PEG bubble lipoplex-
es,(39) we assumed that NF-jB decoy would be introduced
into the cytoplasm of TAMs directly by the collapse of Man-
PEG bubble lipoplexes on the surface of TAMs following US
exposure.
It is assumed that the mechanism of the phenotypic conver-
sion of TAMs is related to a reduction of intranuclear p50 in
TAMs. Nuclear factor-jB is composed of p50 and p65;(40–42)
p65 possesses a transactivation domain, but p50 does not.
Therefore, the NF-jB heterodimer p65 ⁄p50 can activate the
transcriptional process, which is essential for Th1 immune
responses. In contrast, p50 ⁄p50 homodimers inhibit transcrip-
tional activation.(40–43) Saccani et al. and Porta et al. have
reported that abundant nucleic accumulation of the p50 NF-jB
subunit in TAMs inhibits M1 polarization, and ablation of the
p50 subunit prevents TAM polarization to the M2 pheno-
type.(24,25) The NF-jB decoy used in this study disrupted
NF-jB activity by binding to NF-jB p50, and we showed a
reduction of nucleic p50 in TAMs after NF-jB decoy transfec-
tion (Fig. 2a). These results suggest that phenotypic conversion
of TAMs is induced by efficient NF-jB decoy transfection into
TAMs.
We determined the changes of both Th1 and Th2 cytokine
expression in TAMs with or without NF-jB decoy transfec-
tion. As shown in Figure 3(a), mRNA expression of the Th2
cytokine IL-10 in TAMs transfected with the NF-jB decoy by
Man-PEG bubble lipoplexes and US exposure was significantly
lower compared with that in other groups. In contrast, mRNA
levels of Th1 cytokines IL-12, TNF-a, and IL-6 in TAMs
transfected with the NF-jB decoy by Man-PEG bubble lipo-
plexes and US exposure were the highest (Fig. 3b–d). These
alterations of cytokine expression levels are in line with our
previous report that showed the conversion of cytokine produc-
tion profiles in TAMs by NF-jB decoy transfection into solid
tumor (colon26)-bearing mice.(27) In addition, NF-jB decoy
transfection by Man-PEG bubble lipoplexes and US exposure
did not affect the viability of TAMs (data not shown). These
results suggest that TAMs transfected with a NF-jB decoy by
Man-PEG bubble lipoplexes and US exposure convert their
phenotype from M2 toward M1.
(a) (b)
Fig. 2. Amounts of intranuclear p50 (a) and p65
(b) in tumor-associated macrophages following in
vivo nuclear factor-jB (NF-jB) decoy transfection
using ultrasound (US)-responsive and mannose-
unmodified liposome ⁄NF-jB decoy complexes
(Bare-PEG bubble lipoplexes) or ultrasound (US)-
responsive and mannose-modified liposome ⁄NF-jB
decoy complexes (Man-PEG bubble lipoplexes)
(10 lg NF-jB decoy) with or without US exposure at
12 h post-transfection. Each value represents the
mean + SD (n = 3). *P < 0.05, **P < 0.01 compared
with non-treatment (N.T.).
Fig. 1. In vivo transfection efficiency of the nuclear
factor-jB (NF-jB) decoy into tumor-associated
macrophages by ultrasound (US)-responsive and
mannose-unmodified liposome ⁄NF-jB decoy com-
plexes (Bare-PEG bubble lipoplexes) and ultrasound
(US)-responsive and mannose-modified liposome
⁄NF-jB decoy complexes (Man-PEG bubble
lipoplexes) (10 lg NF-jB decoy) with (+) or without
() US exposure. Fluorescent intensity of the
FAM-labeled NF-jB decoy in tumor-associated
macrophages at 1 h after addition of bubble
lipoplexes. **P < 0.01.
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To investigate the therapeutic potential of NF-jB decoy
transfer by mannose-modified bubble lipoplexes into TAMs
against EAC-bearing mice, we measured ascitic volumes and
the number of EAC cells in ascites, and monitored body
weight changes and survival of EAC-bearing mice. Saccani
et al.(24) have reported that TAMs cultured in standard condi-
tions for 24-72 h showed altered characteristics, such as cyto-
kine expression. Taking this into consideration, we designed a
protocol in which EAC-bearing mice were i.p. injected with
NF-jB decoys three times every other day. As shown in Fig-
ure 5(a,b), the strongest inhibitory effects on ascites and EAC
cell accumulation in the peritoneal cavity were observed in
mice with NF-jB decoy transfer by Man-PEG bubble lipoplex-
es and US exposure. As we have confirmed that NF-jB decoy
transfer had no direct cytotoxic effect on EAC cells (Fig. S1),
this therapeutic effect may be attributed to the regulation of
TAM function. Furthermore, we observed a significant prolon-
gation of survival and suppression of the increase of body
weight (Fig. 5c,d). Taken together, our results indicate that
NF-jB decoy transfer by Man-PEG bubble lipoplexes and US
exposure into TAMs is an effective method to inhibit MA pro-




Fig. 4. Effect of in vivo nuclear factor-jB (NF-jB)
decoy transfection by ultrasound (US)-responsive
and mannose-unmodified liposome ⁄NF-jB decoy
complexes (Bare-PEG bubble lipoplexes) or
ultrasound (US)-responsive and mannose-modified
liposome ⁄NF-jB decoy complexes (Man-PEG bubble
lipoplexes) (10 lg NF-jB decoy) with or without US
exposure on tumor angiogenesis. (a) Vascular
endothelial growth factor (VEGF) concentration in
ascites collected 10 days after Ehrlich ascites
carcinoma cell inoculation into mice. (b) mRNA levels
of VEGF in tumor-associated macrophages collected
24 h post-transfection. Data are represented as the
mean + SD (n = 4). *P < 0.05, **P < 0.01 compared
with non-treatment (N.T.). (c) Peritoneal
angiogenesis at 10 days after Ehrlich ascites
carcinoma cell inoculation into mice. The
peritoneum was cut open and the inner lining of the
peritoneal cavity was photographed.
(a) (b)
(c) (d)
Fig. 3. Effect of in vivo nuclear factor-jB (NF-jB)
decoy transfection by ultrasound (US)-responsive
and mannose-unmodified liposome ⁄NF-jB decoy
complexes (Bare-PEG bubble lipoplexes) or
ultrasound (US)-responsive and mannose-modified
liposome ⁄NF-jB decoy complexes (Man-PEG bubble
lipoplexes) (10 lg NF-jB decoy) with or without US
exposure on cytokine mRNA expression in tumor-
associated macrophages. mRNA levels of
interleukin-10 (IL-10) (a), IL-12 (b), tumor necrosis
factor-a (TNF-a) (c), and IL-6 (d) in tumor-associated
macrophages collected at 24 h post-transfection.
Data are represented as the mean + SD (n = 4).
*P < 0.05, **P < 0.01 compared with non-treatment
(N.T.).
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Angiogenesis is strongly linked to tumor growth and
metastasis.(30–32) It is also known that ascitic tumor growth
including EAC is dependent on angiogenesis, and inhibition of
angiogenesis exerts a significant antitumor effect in EAC-bear-
ing mice.(30,31,44,45) Because TAMs are reported to promote
tumor angiogenesis through expression of VEGF,(17–19) pheno-
typic regulation of TAMs is expected to suppress angiogenesis
in EAC-bearing mice. As shown in Figure 4, VEGF expression
in ascites and in TAMs were significantly reduced and perito-
neal angiogenesis was more suppressed in the mouse perito-
neal dissemination model of EAC transfected with the NF-jB
decoy by Man-PEG bubble lipoplexes and US exposure. In
addition, we have observed that NF-jB decoy transfer had no
direct cytotoxic effect on vascular endothelial cells (normal
HUVECs) (Fig. S1). Taking these factors into consideration,
suppression of angiogenesis by NF-jB decoy transfer into
TAMs might be supported by phenotypic conversion of TAMs
and their antitumor effect in the mouse peritoneal dissemina-
tion model of EAC.
In conclusion, we succeeded in efficiently delivering a
NF-jB decoy into TAMs by Man-PEG bubble lipoplexes and
US exposure in a mouse peritoneal dissemination model of
EAC. Moreover, we observed potent antitumor effects against
MA by efficient transfer of the NF-jB decoy into TAMs.
Although further studies are needed to clarify the mechanism,
efficient NF-jB decoy transfer by Man-PEG bubble lipoplexes
with US exposure into TAMs may be a novel approach for
MA treatment.
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